RecruitingPhase 1Phase 2NCT03375983

Plasmodium Immunotherapy for Advanced Cancers

Clinical Study of Plasmodium Immunotherapy for Advanced Cancers

Sponsor

CAS Lamvac Biotech Co., Ltd.

Enrollment

20 participants

Start Date

Nov 23, 2017

Study Type

INTERVENTIONAL

Conditions

Advanced cancers

Summary

The purpose of this study is to evaluate the safety of Plasmodium immunotherapy and preliminarily evaluate the effectiveness of Plasmodium immunotherapy for advanced cancers.The treatment will last 3-6 months from the day of successful infection and will be terminated by antimalarial drugs.

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called Blood-stage infection of P.vivax for people with advanced cancers. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 70 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALBlood-stage infection of P.vivax

The P. vivax infected blood will be confirmed to follow the national standard of blood donation to ensure that only P. vivax is included, excluding the presence of P. falciparum. Exclude other infectious diseases according to the test of national standard of blood donation.

Locations(1)

Guangzhou Fuda Tumor Hospital

Guangzhou, Guangdong, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03375983

Related Trials

Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers

NCT0726070811 locations